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Abstract: Background: Sacubitril/valsartan has been shown to be superior to enalapril in reducing 
the risks of death and hospitalization for heart failure (HF). However, knowledge of the impact on 
cardiac performance remains limited. We sought to evaluate the effects of sacubitril/valsartan on 
clinical, biochemical and echocardiographic parameters in patients with heart failure and reduced 
ejection fraction (HFrEF). Methods: Sacubitril/valsartan was administered to 205 HFrEF patients. 
Results: Among 230 patients (mean age 59 ± 10 years, 46% with ischemic heart disease) 205 (89%) 
completed the study. After a follow-up of 10.49 (2.93 ± 18.44) months, the percentage of patients in 
New York Heart Association (NYHA) class III changed from 40% to 17% (p < 0.001). Median N–
Type natriuretic peptide (Nt-proBNP) decreased from 1865 ± 2318 to 1514 ± 2205 pg/mL, (p = 0.01). 
Furosemide dose reduced from 131.3 ± 154.5 to 120 ± 142.5 (p = 0.047). Ejection fraction (from 27± 
5.9% to 30 ± 7.7% (p < 0.001) and E/A ratio (from 1.67 ± 1.21 to 1.42 ± 1.12 (p = 0.002)) improved. 
Moderate to severe mitral regurgitation (from 30.1% to 17.4%; p = 0.002) and tricuspid velocity 
decreased from 2.8 ± 0.55 m/sec to 2.64 ± 0.59 m/sec (p < 0.014). Conclusions: Sacubitril/valsartan 
induce “hemodynamic recovery” and, consistently with reduction in Nt-proBNP concentrations, 
improve NYHA class despite diuretic dose reduction.  
Keywords: heart failure; sacubitril/valsartan; neprilysin inhibition; reduced ejection fraction; 
echocardiography; Nt-ProBNP; hemodynamic; remodeling 
 
1. Introduction 
Liking renin-angiotensin-aldosterone system (RAAS) blockade with natriuretic peptide system 
enhancement may bear specific therapeutic benefits to patients with heart failure and reduced 
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ejection fraction (HFrEF). The first-in-class angiotensin receptor neprilysin inhibitor (ARNI) 
sacubitril/valsartan combines the angiotensin II type-1 receptor blocker (ARB) valsartan with the 
neprilysin inhibitor sacubitril. Sacubitril/valsartan was superior to enalapril in decreasing risks of 
death and new admission for HF in patients with HFrEF in the Prospective Comparison of ARNI 
with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-
HF) study [1]. However, the effect of sacubitril/valsartan on cardiac performance in patients with 
HFrEF remains limited [2,3]. Therefore, in this study, we attempted to assess the effects of 
sacubitril/valsartan on clinical, biochemical and echocardiographic, parameters in HFrEF patients. 
2. Experimental Section 
Study Design and Patient Selection: The study was conducted in our outpatient HF clinic center, 
which is mainly focused on HFrEF patients evaluated for heart transplantation, between 1st 
September, 2017 and 15th January, 2019, and was approved by the Institutional Research Review 
Board of the Istituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione (ISMETT) center 
in Palermo, Italy. In this prospective observational single center study, sacubitril/valsartan was 
administered to patients with HFrEF, in addition to recommended therapy [2]. The aim of the study 
was to evaluate the effects of sacubitril/valsartan on clinical, biochemical and echocardiographic 
parameters, recorded at baseline and after follow-up.  
Patients were included in the study in accordance with the following inclusion criteria:  
(1) symptomatic heart failure defined as New York Heart Association (NYHA) class II-III;  
(2) left ventricular ejection fraction (LVEF) below 35% measured by echocardiography;  
(3) pretreatment with an individual optimal dose of angiotensin-converting enzyme 
inhibitor (ACE-I) or ARB for at least 6 months;  
(4) arterial blood pressure ≥100 mmHg;  
(5) serum potassium (K+) level <5.4 mEq/L.  
Exclusion criteria were as follows:  
(1) Hospital admission for HF within 90 days before ambulatory evaluation; 
(2) Myocardial revascularization within 180 days before ambulatory visit; 
(3) Concomitant implantation of cardiac resynchronization therapy (CRT) and/or 
percutaneous mitral valve treatment during study follow-up or in the previous 6 
months; 
(4) Presence of congenital heart disease; 
(5) Severe liver insufficiency (Child–Pugh C); 
(6) History of angioedema. 
All patients provided informed consent for participation, and the protocol was approved by the 
research ethics committee in accordance with the principles of the Declaration of Helsinki and 
national regulations.  
Study Procedures: To assess clinical stability, patients were assessed in our outpatient clinic at 
the enrolment phase (baseline visit). Medical history, physical exam, weight, blood pressure, NYHA 
class, 12 lead electrocardiogram (ECG), and laboratory analysis comprehensive of biomarkers 
including N-terminal pro-brain natriuretic peptide (NT-proBNP) were obtained every 1 month to 
undertake sacubitril/valsartan dose up-titration and then every 6 months. Doses of 
sacubitril/valsartan were prescribed according to established recommendations [4]. The 
recommended starting dose was 49/51 mg twice daily. Patients were switched from an ACE-I after a 
36 hour washout period. For patients with severe renal impairment (estimated glomerular filtration 
rate [eGFR] <30 mL/min), moderate liver insufficiency (Child–Pugh B), hypotensive (<110 mmHg), 
or taking low doses of ACE-I or ARB, the starting dose was 24/26 mg twice-daily. Up-titration was 
operated every 4 weeks if tolerated by the patient. Furosemide dose modifications were conceded 
during follow-up. Safety and tolerability assessments were performed, including monitoring and 
recording of all adverse events and their relationship to the study drug. Two hundred thirty were 
initially enrolled. After the run-in phase (one month), eight patients discontinued sacubitril/valsartan 
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because of hypotension, four because of worsening renal function and two because of skin erythema: 
Two hundred and sixteen patients were finally evaluated. 
Echocardiography: A standard 2-dimensional and Doppler transthoracic echocardiogram was 
performed at two time points (baseline assessment and 6 months after the initiation of 
sacubitril/valsartan) in all patients. All ultrasound examinations were done with a commercially 
available echocardiographic instrument (Vivid 9 System, Vingmed, General Electric Healthcare and 
Philips Medical Systems, EPIC, Cary, NC, USA). LVEF and volumes were measured from apical 
views using the modified biplane Simpson method, as previously described [5]. Volumes and mass 
were indexed to the body surface area. The right ventricular (RV) longitudinal systolic function was 
assessed by tricuspid annular plane systolic excursion (TAPSE). Color Doppler was used to 
qualitatively assess mitral regurgitation (MR) degree. Assessment of diastolic function was made by 
trans-mitral early (E wave velocity) and late (A wave velocity) Doppler flow waves, E/A ratio, and E 
deceleration time, and by measuring the early diastolic pulsed wave tissue Doppler (PW-TDI) at the 
medial and lateral mitral annulus (e’). E/e’ ratio was used as a parameter of LV end-diastolic filling 
pressure (LVEDP) [6]. Tricuspid regurgitation (TR) velocity was measured in order to estimate 
systolic pulmonary arterial pressure and inferior vena cava diameter variation as a surrogate for 
central venous pressure. Images were analyzed offline by two expert investigators blinded to clinical 
factors as well as drug treatment. 
Statistical analysis was executed using SPSS Statistics 25 software (IBM). Continuous variables 
are defined by mean (SD), or by median and interquartile range, in case of non-normal distribution. 
Categorical variables were described as number (percentages). Two hundred and five patients were 
followed-up in our outpatient clinic, and changes from baseline were tested by paired t-test or 
McNemar test, respectively. A p-value <0.05 was considered statistically significant. 
3. Results 
3.1. Baseline Evaluations 
A total of 216 patients were prospectively enrolled. However, five patients discontinued 
sacubitril/valsartan because they experienced hypotension, four patients because of acute on chronic 
HF and two patients had ventricular arrhythmia. Therefore, 205 (89%) patients were included in the 
final analysis with a median follow-up of 10.49 m (range 2.93–18.44) months. The mean age was 59 ± 
10 years, which is younger than general HFrEF population, but consistent with patients usually 
referred to a transplantation center, 15% females, 46% with ischemic heart disease, 62% with NYHA 
functional class II and 17% on atrial fibrillation. Baseline characteristics of patients are presented in 
Table 1. 
Table 1. Baseline characteristics of patients. 
Patients Characteristics N (%) 
Patients 205 
Age (mean ± SD) 59 ± 10 
Female sex 31 (15) 
BSA (mean ± SD) 2 ± 0.2 
ETIOLOGY  
Ischemic 95 (46) 
Non Ischemic 110 (54) 
NYHA   
II 128 (62) 
III  77 (38) 
COMORBIDITY  
hypertension 90 (45) 
Diabetes  63 (32) 
Atrial fibrillation 35 (17) 
COPD 7 (3) 
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MEDICAL THERAPY  
FUROSEMIDE 180 (88) 
MRA 174 (85) 
ACE- I /ARB 100 (205) 
β-BLOCKERS 197 (96) 
IVABRADINE 37 (18) 
ELECTRICAL THERAPY   
ICD  164 (80) 
CRT 51 (25)  
Values are mean ± standard deviation. BSA, Body surface area; NYHA, New York Heart Association; 
COPD, chronic obstructive pulmonary disease; MRA, mineralocorticoid receptor antagonist; ACE-I, 
angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; ICD, intracardiac 
defibrillator; CRT, cardiac resynchronization therapy. 
The mean (SD) of systolic blood pressure was 118.5 ± 15 mm Hg. The median of NT-proBNP 
levels, eGFR (Modification of Diet in Renal Disease [MDRD] Study) equation dosages, creatinine 
concentrations and serum potassium at baseline were 1865 ± 2318 pg/mL, 69.4 ± 23.1 mL/min/1.73 m2, 
1.2 ± 0.35 mg/dL, 4.14 ± 0.44 mEq/L respectively. Beta-blockers, mineralocorticoid receptor antagonist, 
and furosemide were administered in 96%, 85%, and 88% of patients, respectively. The mean daily 
furosemide dose was 131.3 ± 154.5 mg. Eighty percent of patient underwent to cardiac defibrillator 
(ICD) implantation and 25% of patients received CRT device with ICD. The starting dose of 
sacubitril/valsartan was 24/26 mg twice daily in 77% of patients. The dose of 49/51 mg was 
administered in 23% of patients. Mean baseline values of LVEF, E/A ratio, left atrial volume index 
(LAVi), were 27 ± 5.9%, 1.67 ± 1.21 and 54.2 ± 22.6 mL respectively. The percentage of patients with 
moderate to severe functional MR was 30.1% and the mean baseline values of TR velocity was 2.8 ± 
0.55 m/sec (Table 2).  
Table 2. Changes in clinical, sacubitril/valsartan dose, biochemical and echocardiographic 
parameters. 
 Baseline Follow-up p Value 
SBP (mmHg) 118.5 ± 15 115,4 ± 16.9 0.042 
DBP (mmHg) 73 ± 10.3 67.5 ± 9.3 <0.001 
NT-proBNP (pg/mL) 1865 ± 2318 1514 ± 2205 0.01 
Creatinine (mg/dL) 1.2 ± 0.35 1.31 ± 0.57 0.052 
eGFR (mL/min/1.73 m2) 69.4 ± 23.1 65.3 ± 23.2 0.012 
potassium (mEq/L) 4.14 ± 0.44 4.17 ± 0.44 0.611 
Furosemide dose (mg) 131.3 ± 154.5 120 ± 142.5 0.047 
SACUBITRIL/VALSARTAN    
24/26 (mg/bid) 77 39  
49/51 (mg/bid) 23 34  
97/103 (mg/bid) 0 27  
FE (%) 27 ± 5.9 30 ± 7.7 <0.001 
EDVi (mL/m2) 120.5 ± 31.4 120,7 ± 33 0.932 
MR mod/sev (%)  30.1 17.4 0.002 
E/A 1.67 ± 1.21 1,42 ± 1.12 0.002 
E/e’ 14.79 ± 6.10 13.85 ± 6.09 0.194 
LAVi (mL/m2) 54.2 ± 22.6 52,4 ± 19.1 0.202 
TR velocity (m/s) 2.8 ± 0.55 2.64 ± 0.59 0.014 
TAPSE (mm) 19.03 ± 4.55 19.28 ± 3.62 0.472 
SBP: Systolic blood pressure; DBP: Diastolic blood pressure; Nt-proBNP, N-terminal pro–B-type 
natriuretic peptide. eGFR, estimated glomerular filtration rate; EF, ejection fraction; EDVi, endiastolic 
volume index.; MR, mitral regurgitation from moderate to severe grade; E/A: peak e-wave velocity/ 
peak a-wave velocity ratio; E/e’ peak: e-wave velocity divided by mitral annular e’ velocity (average) 
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ratio; LAV-i, left atrial volume index; RA, right atrium; TR velocity: tricuspid regurgitation peak 
velocity; TAPSE, tricuspid annular plane systolic excursion. 
3.2. Change in Clinical Characteristics, ARNI dose and Laboratory Data  
After a median follow-up of 10.49 months (2.93 ± 18.44 months), percentage of patients HYHA 
class II increase from 60% to 73% and the number of patients in NYHA class III decrease from 40% to 
17% (p < 0.001).  
Systolic and diastolic blood pressure decreased with treatment (p = 0.009 and p <0 .001, 
respectively). The dose of sacubitril/valsartan 49/51 mg twice daily was administered in 34% of 
patients. In 39% of patients, the initial dosage of 24/26 mg twice daily was maintained. The dose was 
up titrated until 97/103 mg twice daily only in the 27% of patients, because of symptomatic 
hypotension. The median furosemide dose decreased from 131.3 ± 154.5 mg at baseline to 120 ± 142.5 
mg after follow-up (p = 0.047), see Table 2. Initiation and titration of sacubitril-valsartan was 
associated with a reduction in NT-proBNP concentration (1514 ± 2205 pg/mL; p =0.01). We observed 
significant changes, but not clinically relevant, in eGFR (65.3 ± 23.2 mL/min/1.73 m2; p = 0.012). Only 
two patients with eGFR <30 mL/min/1.73 m2 were included and consequently we did not perform 
subgroup analysis  
In these two patients, Sacubitril/Valsartan was less titrated compared to patients with eGFR ≥60 
mL/min/1.73 m2 and moreover, they did not experience eGFR worsening during follow-up.  
No variation in creatinine concentrations and in serum potassium (1.31 ± 0.57 mg/mL; p = 0.052) 
(4.17 ± 0.44 mEq/L, p= 0.611) were founded, see Table 2.  
3.3. Change in Echocardiographic Measurements. 
Patients exhibited a mild but significant improvement in LVEF (30 ± 7.7%; p =0.001). The changes 
in the E/A-wave ratio from baseline to follow-up were (1.42 ± 1.12; p =0.002), on the contrary there 
was no significant change in E/e’ (from 14.79 ± 6.10 to 13.85 ± 6.09; p = 0.194). Treatment with 
sacubitril-valsartan was also associated with significant reduction of the percentage of patients with 
moderate to severe MR (from 30.1% to 17.4%, p = 0.002). In addition, TR velocity decrease from 2.8 ± 
0.55 m/sec to 2.64 ± 0.59 m/sec (p < 0.014), (Table 2).  
3.4. Safety 
During follow-up, five (2%) patients discontinued sacubitril/valsartan because they experienced 
hypotension and four (2%) patients because of acute on chronic HF. In two (1%) patients, worsening 
renal function was observed.  
3.5. Outcomes 
During follow-up, no patients died. In the group of ischemic cardiomyopathy, we observed one 
hospital admission because of acute on chronic HF and one admission because ventricular 
arrhythmia.  
Concerning non ischemic cardiomyopathy, we found one acute on chronic hospitalization. 
4. Discussion 
This prospective observational study of patients with HFrEF showed that switching to 
sacubitril/valsartan may generate “hemodynamic recovery” by reducing left ventricular filling 
pressure, MR and finally pulmonary artery systolic pressure. This hemodynamic effect in association 
with the reduction of Nt-proBNP may ameliorate functional class capacity and identify patients in 
which diuretic withdrawal could be safely performed (Figure 1).  
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Figure 1. Hemodynamic recovery. Sacubitril/valsartan reduced E/A ratio, MR, TR velocity and Nt-
ProBNP concentration. This hemodynamic effect ameliorates the NYHA class and reduce diuretic 
dose at follow-up. MR, mitral regurgitation from moderate to severe grade; E/A: peak e-wave 
velocity/ peak a-wave velocity ratio; TR velocity: tricuspid regurgitation peak velocity. 
In this study, we evaluated the effect of switching to sacubitril/valsartan therapy in HFrEF 
patients through a multiparametric approach, that is NT-proBNP levels, echocardiography, and 
NYHA Class and all collected data were used to test the hypothesis that sacubitril/valsartan may 
confer an early comprehensive and global benefit to HFrEF patients.  
We decided to exclude patients with recent admission because of acute on chronic HF so to select 
stable patients on firm medical regimen. In addition to their vasodilatatory, natriuretic, and diuretic 
effects, natriuretic peptides inhibit the RAAS, sympathetic nervous system, and consequent release 
of antidiuretic hormone, improve myocardial relaxation and vagal tone, and have antifibrotic and 
antihypertrophic properties [7,8]. Mechanistically, sacubitril is implicated in attenuating 
cardiomyocyte cell death, hypertrophy, and impaired myocyte contractility [9]. Based on these 
preclinical and mechanistic evaluations of sacubitril, the incremental beneficial effect systolic and 
diastolic function might seem more intuitive than expected. However, prospective data regarding 
sacubitril-valsartan and cardiac remodeling are limited: Martens and colleagues [2] reported a 5% 
mean improvement in LVEF after a follow-up period of 4 months. The recent PROVE-HF study [3] 
adds information regarding associations between ARNI therapy, change in NT-proBNP, and cardiac 
remodeling. Reduction in NT-proBNP following treatment with sacubitril-valsartan was associated 
with an increase in LVEF, and reductions in indexed LV and LA volumes as well as E/e′ ratio. In line 
with these findings we found a mild but significant improvement in cardiac function measured by 
LVEF, confirming the potential LV reverse remodeling effect mediated by sacubitril/valsartan but 
neither significant reductions in LV and LA volume nor in E/e’ ratio was noticed. In our opinion this 
inconsistency can be explained by the fact that in our study patients had significantly dilated 
ventricular and atrial volumes and higher NT-proBNP values, which, in conclusion, would suggest 
a more advanced HF disease than that of the PROVE HF study [3], needing more time to observe 
reverse remodeling. 
Moreover, consistently with previous study [2] we reported a reduction in E/A ratio as well as 
improvement of MR severity [10]. Both are important prognostic measures, reflecting the magnitude 
and chronicity of elevated cardiac filling pressures, LV negative remodeling and fluid congestion.  
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Although qualitatively assessed, the MR grading reduction it has been further confirmed and 
proven by the reduction in TR velocity that means pulmonary artery systolic pressure lowering. 
These data are unique and fascinating and are linked with the significant improvement in NYHA 
class observed in our population. 
Coherently with echocardiographic measurements, neprilysin inhibition mediated by sacubitril 
acutely amplified the hemodynamic effects of natriuretic peptides determining natriuresis and 
vasodilation [11,12] which resulted in decreased neurohormonal activation as our data have 
demonstrated by NT-proBNP concentrations abatement at follow-up.  
In facts, reduction in NT-proBNP concentration was strongly associated with outcomes in 
PARADIGM-HF [1]. On the other hand, studies have suggested that a lack of NT-proBNP reduction 
after therapy for HFrEF is associated with worse left ventricular size and function [13,14]. 
Our results suggest that patients with NT-proBNP reduction following ARNI initiation are likely 
to experience reverse cardiac remodeling.  
Improving in filling pressure, MR degree and pulmonary pressure in tandem with a small yet 
significant improvement in EF, that is “hemodynamic recovery”, effectively improved NYHA class 
and exertional dyspnea.  
In a recent metanalysis of twenty studies enrolling 10,175 patients, ARNI improved functional 
capacity in patients with HFrEF, including increasing NYHA class and 6 minute walking distance. 
Moreover, ARNI outperformed angiotensin-converting enzyme inhibitors/angiotensin receptor 
blockers in terms of cardiac reverse remodeling with striking changes in left ventricular EF, diameter, 
and volume [15]. 
Confirming these data, we found a reduction of percentage of patients in NYHA class III and an 
increasing number of patients in NYHA class I and II at follow-up (Figure 1).  
These data are in line with our previously published results showing a significant improvement 
in well-known surrogates of cardiac performance such as peak VO2 and O2 pulse as well as others 
main prognostic-relevant CPET parameters after initiation of sacubitril/valsartan [16].  
Furthermore, this “hemodynamic recovery” in association with Nt-proBNP concentration 
reduction, could lead to identify patients in which diuretic withdrawal strategy can be safely 
undertaken [17]. As we founded in our study reducing the mean diuretic dose, allows avoiding a 
significant deterioration of renal function, [18] and electrolyte imbalance.  
Interestingly treatment with sacubitril/valsartan was associated with more loop diuretic dose 
reductions and fewer dose increases compared with enalapril in the PARADIGM-HF study [19], 
suggesting that treatment with sacubitril/valsartan may reduce the relative requirement for loop diuretics 
in patients with heart failure with reduced ejection fraction. The reduced relative need for diuretics in 
patients treated with sacubitril/valsartan may potentially be secondary to the natriuretic effects of 
sacubitril or the presumed improvement in hemodynamics that may occur with sacubitril/valsartan.  
Loop diuretic use has been associated in prior studies with worse outcomes in heart failure. 
Several mechanisms have been proposed by which loop diuretics may increase risk of mortality: 
neurohormonal activation electrolytes depletion, serious cardiac arrhythmias [20,21], as well as an 
increased risk of cardio-renal syndrome [22] have all been reported in the literature. For this reason, 
as we have already demonstrated [17], diuretic therapy can and should be suspended in well-
selected, asymptomatic, patients with HFrEF after adequate therapeutic neuro-hormonal modulation 
to preserve renal function. Consistently with Damman et al. [23] we have observed a slight worsening 
in eGFR that anyhow did not reclassify patients in terms of chronic kidney disease severity and was 
not associated to any change in creatinine or serum potassium levels. On the contrary, Spannella et 
al. [24] showed an eGFR improvement in patients on Sacubitril/Valsartan. In our opinion, this 
inconsistency can be explained by significantly higher dosages of MRA and loop diuretics taken by 
our patients as compared to the heretofore mentioned study.  
This study has a number of limitations. Firstly, the study was not randomized. However, 
prospective longitudinal studies with multiple blinded assessors are a well-accepted design for 
evaluating echocardiographic and cardiopulmonary changes. Secondly, an important limitation of 
this study is the relatively small sample size and lack of a control group. Our study did not show 
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significant reversal in EDVi, although other study observed significant decrease in MR degree 
severity and in LV volumes [Martens] after switching to sacubitril/valsartan.  
Echocardiography is a standard imaging method for the evaluation of MR, but it is not as 
accurate as cardiac MRI for measurement of LV volumes.  
However, this study enrolled 80% of patients with ICD and 25% with CRT hampering optimal 
imaging acquisition for magnetic resonance imaging.  
Our choice of echocardiography as the primary imaging tool could be the limitation for 
assessment of LV remodeling.  
In addition, some echocardiographic parameters useful in the assessment of reverse remodeling 
(LV mass index; strain analysis) were not performed.  
MR was visually assessed because quantitative assessment of functional MR could be unreliable: 
the PISA method is limited by its radius which is frequently not constant, and the geometry of the 
PISA varies (ellipsoidal shape) underestimating the degree of functional MR.  
Vena contracta was not measured as well because intermediate values are not accurate at 
distinguishing moderate from mild or severe MR (large overlap); they usually require the use of 
another method for confirmation. 
Furthermore, the magnitude of reverse remodeling associated with the reduction in MR entity 
might have been substantially underestimated with shorter follow-up. 
5. Conclusions 
In summary, our findings are strongly suggestive of “hemodynamic recovery” in which a 
modulation of neurohormonal activation determined by sacubitril/valsartan may lead to a 
hemodynamic effect that may impact cardiac hemodynamic and in association with Nt-proBNP 
concentration abatement could lead to a ameliorate NYHA class and reduce diuretics administration 
and consequently to preserve renal function. 
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